| OCX Stock | | | USD 3.30 0.20 5.71% |
COO
Albert Parker is Chief Operating Officer of OncoCyte Corp since 2018.
| Tenure | 7 years |
| Phone | 949 409 7600 |
| Web | https://www.oncocyte.com |
OncoCyte Corp Management Efficiency
The company has Return on Asset of
(0.1884) % which means that on every $100 spent on assets, it lost $0.1884. This is way below average. In the same way, it shows a return on shareholders' equity
(ROE) of
(1.6532) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities.
OncoCyte Corp has 2.87
M in debt with debt to equity
(D/E) ratio of 0.05, which may show that the company is not taking advantage of profits from borrowing. OncoCyte Corp has a current ratio of 3.42, demonstrating that it is
liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for OncoCyte to invest in growth at high rates of return.
Similar Executives
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Oncocyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. OncoCyte Corp (OCX) is traded on NASDAQ Exchange in USA. It is located in 15 Cushing, Irvine, CA, United States, 92618 and employs 43 people. OncoCyte Corp is listed under Biotechnology category by Fama And French industry classification.
Management Performance
OncoCyte Corp Leadership Team
Elected by the shareholders, the OncoCyte Corp's board of directors comprises two types of representatives: OncoCyte Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoCyte. The board's role is to monitor OncoCyte Corp's management team and ensure that shareholders' interests are well served. OncoCyte Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoCyte Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrea James, Chief Officer | |
| Michael West, Director, CEO of Biotime Inc and President of Biotime Inc | |
| Ekkehard MD, Chief Officer | |
| Joshua Riggs, Interim Officer | |
| Tony Kalajian, Senior Vice President Chief Accounting Officer | |
| Andrew Last, Independent Director | |
| William Annett, Advisor | |
| Sara Riordan, Director Education | |
| Albert Parker, Chief Operating Officer | |
| Lyndal Hesterberg, Chief Scientific Officer | |
| Robert Seitz, Head Oncology | |
| James Liu, Controller, Director | |
| YuhMin Chiang, Senior Development | |
| Douglas Ross, Chief Medical Officer | |
| Melinda Griffith, Independent Director | |
| Anish John, Chief Officer | |
| Peter Hong, General VP | |
| Andrew Arno, Independent Director | |
| Gisela Paulsen, COO Pres | |
| Ronald Andrews, President, Chief Executive Officer, Director | |
| Cavan Redmond, Independent Chairman of the Board | |
| Padma Sundar, Senior Vice President - Marketing and Market Access | |
| MD FACP, Consulting Officer | |
| Mitchell Levine, Chief Financial Officer | |
| Sandra ODonald, Senior Operations | |
OncoCyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoCyte Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to
measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to
predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.